Feed Hype & Hope updates directly to your favorite news aggregator such as My Yahoo!, NewsGator or FeedDemon.
Published by Zoomedia, Inc.
Zoomedia is a leading communications agency dedicated to increasing our clients' value through insightful and imaginative creative programs for the life sciences industry.
For questions or comments about this site, please contact hypeandhope@zoomedia.com.
©2008 Zoomedia, Inc.
All rights reserved.
Human clinical trials are the only way of evaluating whether new diagnostics, drugs, experimental medical devices, and surgical techniques actually work, and therefore well-functioning trials are absolutely critical to medical progress. Recruiting volunteers to participate remains one of the costliest aspects of the drug development process. Reducing the length of a clinical trial by just one month by improving patient recruitment could not only save lives, but also generate additional revenue to reinvest in the research and discovery of new therapies. Staying on the path we are on is simply not an option if we want to accelerate the search for cures to deadly and debilitating diseases. "Clinical Trials Recruitment and Retention: Best Practices and Promising Approaches" published by FasterCures, www.fastercures.org
Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers
>> Read the StoryA lot of advancement in breast cancer treatment has come from clinical trials. Four relatively young local women are all taking part in various studies, hoping to improve breast cancer treatment for all women.
>> Read the StoryPharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.
>> Read the StoryStem Cell Therapeutics Corp. has received results from the Data Safety Monitoring Board that provides oversight for the Company’s Phase IIb REGENESIS trial. The DSMB has completed a safety analysis and has recommended the trial continue as per the protocol.
>> Read the StoryPharmaceutical manufacturers Affymax and Takeda announced they will suspend co-development of HematideTM to treat chemotherapy-induced anemia (CIA) and focus all efforts on developing the erythropoiesis-stimulating agent for treatment of anemia associated with chronic kidney disease.
>> Read the StoryA drug offering hope for many post-menopausal women who find sex painful may be inching toward commercialization as a late-stage clinical trial has begun.
>> Read the StoryProtox Therapeutics, a developer of receptor targeted fusion proteins, has completed enrollment of patients for its Phase II study of PRX302 in males with moderate to severe benign prostatic hyperplasia, a common and bothersome urological condition that is said to affect more than one million men in Canada and over 50 million men worldwide.
>> Read the StoryInterMune, Inc. today announced that InterMune has earned a $15 million development milestone under its development collaboration with Roche for the hepatitis C virus (HCV) NS3 protease inhibitor compound ITMN-191 (referred to as R7227 at Roche), currently in a Phase 1b clinical trial in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin).
>> Read the StoryTakeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide™ to treat chemotherapy-induced anemia and to focus all development efforts for Hematide™ on the treatment of chronic kidney disease related anemia.
>> Read the StoryBioTronik reports a business update that indicates the company is moving on a leadership track.
>> Read the StoryOptimer Pharmaceuticals, Inc. today announced that the company has completed enrollment in the second of two planned phase 3 clinical trials evaluating the safety and efficacy of Prulifloxacin for the treatment of infectious diarrhea in travelers.
>> Read the StoryCody Miller was a high school football player who was allergic to ragweed. Douglas Briggs was a doctor coping with pain from an old back injury.
>> Read the StoryTarganta Therapeutics Corporation today announced positive top-line results from a Phase 2 clinical trial investigating the efficacy and safety of oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI.
>> Read the Story